Affordable Access

Publisher Website

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

Authors
Journal
Vaccine
0264-410X
Publisher
Elsevier
Publication Date
Volume
29
Issue
43
Identifiers
DOI: 10.1016/j.vaccine.2011.03.083
Keywords
  • Malaria
  • Vaccine
  • Heterologous Prime-Boost
Disciplines
  • Biology

Abstract

Abstract We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.

There are no comments yet on this publication. Be the first to share your thoughts.